Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Confidence And Knowledge Needed In Europe, Say Experts

Executive Summary

European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.

Advertisement

Related Content

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Dutch Project To Monitor Safety Of Biosimilar Switching
Biosimilars In EU Seeing Reduced Clinical Data Requirements
France Relaxes Stance On Biosimilar Switching
Ten Years On, Access To Biosimilars Still Patchy in EU
Biosimilar Implementation: How US Can Learn From EU
INTERVIEW: The Biosimilar Brain - Celltrion’s Dr. Stanley Hong

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel